A quality risk management model approach for cell therapy manufacturing

Area of Science:

• Regenerative Medicine
• Biotechnology
• Process Engineering

Background:

• Regulatory bodies emphasize risk management for novel cell therapies.
• Existing guidelines lack specific risk analysis methods for clinical cell manufacturing.
• Cell manufacturing faces challenges including automation gaps, human error, tissue heterogeneity, and reagent variability.

Purpose of the Study:

• To identify and address key challenges in cell-based product manufacturing.
• To present a novel risk management model for clinical cell therapy production.
• To evaluate the efficacy and efficiency of risk analysis techniques in this context.

Main Methods:

• Utilized heuristic and pseudo-quantitative Failure Mode and Effect Analysis (FMEA) / Failure Mode and Critical Effect Analysis (FMECA).
• Employed direct estimation of severity, occurrence, and detection.
• Adopted severity/occurrence matrices and Pareto analysis for risk prioritization.

Main Results:

• The FMEA/FMECA approach proved effective and more efficient than Analytic Hierarchy Process (AHP).
• Severity/occurrence matrices and Pareto analysis successfully identified critical failure modes.
• The developed model provides a practical framework for risk mitigation in cell manufacturing.

Conclusions:

• A practical risk management model is established for clinical cell therapy manufacturing.
• Heuristic risk analysis techniques are efficient and effective for this specialized field.
• The approach aids in prioritizing actions to mitigate risks, ensuring safer regenerative medicine products.